Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesEndocrinologyWellsense Health Plan secondary hyperaldosteronism…
    Ask Trek AI about this page
    CurrentWellsense Health PlanPolicy N/A

    Secondary Hyperaldosteronism Documentation Best Practices

    Customize your policy alerts

    Sign up for all wellsense_health_plan policy alerts

    Know when wellsense_health_plan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Guidance for clinicians on documenting secondary hyperaldosteronism (ICD-10: E26.1) to ensure accurate diagnosis capture and linkage to the primary causal condition for WellSense Health Plan members.

    Policy Summary
    PayerWellsense Health Plan
    PolicySecondary Hyperaldosteronism Documentation Best Practices
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Next Review DateN/A
    Key ActionDocument clinical findings (BP, edema, abnormal labs), identify and link the primary condition causing secondary hyperaldosteronism, and include assessment and plan for both conditions.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    E26.1ICD-10 code
    2Example scenarios
    3+Edema severity example
    2Primary cause categories

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Coverage Criteria

    Documentation criteria for accurate diagnosis capture

    Covered when ALL of the following documentation elements are present in the medical record:

    Essential documentation elements: 1) Document clinical findings that led to the diagnosis (e.g., blood pressure, edema, any abnormal labs); 2) Identify the primary condition accountable for the aldosteronism (e.g., heart failure, cirrhosis) and document its status; 3) Use explicit linking language to connect the secondary hyperaldosteronism to the primary diagnosis (e.g., 'due to', 'secondary to', 'caused by', 'associated with'); 4) Include an assessment and plan for both the primary and secondary conditions.

    These are documentation best-practice criteria to ensure accurate diagnosis capture.

    The source document lists common primary causes of secondary hyperaldosteronism without specifying exclusions. Typical etiologies identified include obstructive renal artery disease, renal vasoconstriction (for example with accelerated hypertension), and edematous disorders such as heart failure, cirrhosis with ascites, and nephrotic syndrome. There are no explicit exclusions noted for these causes in the guidance; the focus is on recognizing and documenting the primary condition when capturing a diagnosis of secondary hyperaldosteronism.

    The document does not contain any explicit statements labeling situations or services as not medically necessary. Instead, it provides documentation requirements and best-practice guidance to ensure accurate diagnosis capture, emphasizing elements clinicians should include (clinical findings, identification of the primary condition, explicit linking language, and assessment/plan for both conditions).

    Coding

    Diagnosis Codes demonstrated in examplesICD-10Covered
    E26.1Secondary hyperaldosteronism
    I50.22Chronic systolic congestive heart failure
    K74.60Unspecified cirrhosis of liver

    Provider Actions & Documentation

    Prior Authorization

    Code secondary hyperaldosteronism with the primary diagnosis

    Document E26.1 (Secondary hyperaldosteronism) in the medical record alongside the primary diagnosis code (for example, I50.22 for chronic systolic congestive heart failure or K74.60 for cirrhosis) to show linkage between the secondary condition and its underlying cause.

    Step Therapy

    Document diuretic adjustments and MR antagonist plans

    Include treatment actions in the plan such as diuretic adjustment (e.g., increasing furosemide) and consideration or initiation of a mineralocorticoid receptor antagonist (e.g., spironolactone) when documenting management for secondary hyperaldosteronism due to heart failure or cirrhosis.

    • Example: Furosemide increased to 40 mg daily (heart failure scenario).
    • Example: Add spironolactone 25 mg once daily (cirrhosis scenario).
    • Document referrals when planning MR antagonist initiation (e.g., cardiology, GI).
    Documentation Required

    Document clinical findings and explicit linkage to primary cause

    Record the clinical findings that supported the diagnosis (e.g., blood pressure, presence and severity of edema/ascites, and any abnormal labs), identify the primary condition responsible for aldosteronism and its status, and use explicit linking language (e.g., 'due to', 'secondary to', 'caused by', 'associated with').

    • Include an assessment and plan for both the primary and secondary conditions.
    • Use explicit linking phrasing to tie E26.1 to the primary diagnosis in the note.
    Denial Risk

    Risk of denial or improper diagnosis capture without documented findings/linkage

    If the clinical findings that led to the diagnosis (such as BP, edema, or abnormal labs) or an explicit linkage to the primary condition are not documented, the diagnosis capture may be improper and could lead to administrative issues or denial risk.

    • Failure to identify the primary condition and its status or to use linking language risks incomplete documentation capture.

    Background

    Secondary hyperaldosteronism is increased adrenal production of aldosterone driven by non‑adrenal stimuli and is most often caused by decreased renal blood flow or other systemic conditions. Common mechanisms include reduced renal perfusion from obstructive renal artery disease or renovascular vasoconstriction (such as in accelerated hypertension), and physiologic responses to volume‑overload edematous disorders like heart failure, cirrhosis with ascites, and nephrotic syndrome. Laboratory patterns and the degree of renin and aldosterone elevation can vary by cause, but clinical documentation should focus on the precipitating primary condition and objective findings (for example blood pressure, edema, and relevant abnormal labs) to support the diagnosis.

    Definitions

    Secondary hyperaldosteronism — definition
    DefinitionA condition of increased adrenal production of aldosterone in a nonpituitary, extra-adrenal response to stimuli, usually caused by decreased renal blood flow produced by other primary conditions.
    Typical mechanismIncreased adrenal aldosterone production driven by non‑adrenal stimuli (extra‑adrenal response).
    Common underlying causesDecreased renal blood flow due to other primary conditions (e.g., renovascular disease, accelerated hypertension).
    Associated edematous disordersMay occur with heart failure, cirrhosis, or nephrotic syndrome as contributing primary conditions.
    ICD-10 Code for secondary hyperaldosteronism
    ICD-10 codeE26.1
    Code descriptionSecondary hyperaldosteronism
    Use in documentationReport E26.1 alongside the primary causal diagnosis to accurately capture secondary hyperaldosteronism (e.g., with heart failure or cirrhosis).
    Policy Summary
    PayerWellsense Health Plan
    PolicySecondary Hyperaldosteronism Documentation Best Practices
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Next Review DateN/A
    Key ActionDocument clinical findings (BP, edema, abnormal labs), identify and link the primary condition causing secondary hyperaldosteronism, and include assessment and plan for both conditions.
    SourceLink
    On This Page
    Coverage CriteriaCodingProvider Actions & DocumentationBackgroundDefinitions